New Paradigms in Alzheimer's Disease Drug Development
Eric Siemers, Medical Director, Alzheimer's Disease Team, Eli Lilly
Eric Siemers, M.D. is the Senior Medical Director of the Alzheimer’s Disease Global Development Team at Eli Lilly and Company. He earned his MD with highest distinction from the Indiana University School of Medicine in 1982. After an internship in the Department of Internal Medicine at the Indiana University School of Medicine, he completed his residency in the Department of Neurology in 1986. Prior to joining Lilly, he founded and headed the Indiana University Movement Disorder Clinic; his previous research included investigations of Parkinson’s disease and Huntington’s disease, and he established one of the first centers for surgical PD treatments in the US.
Dr . Siemers currently directs late stage clinical research efforts at Lilly concerning investigational treatments for Alzheimer’s disease, and is more broadly involved with other neurological indications such as Parkinson’s disease. Major research interests include the use of biomarkers in investigational drug research and the development of trial designs that broadly characterize the effects of investigational drugs on chronic diseases.
Dr . Siemers is a founding member and current Chair of the Alzheimer’s Association Research Roundtable. He is a member of the Steering Committee for the Alzheimer’s Disease Neuroimaging Initiative (ADNI). He served as the chair of the Industry Scientific Advisory Board for ADNI in 2007. Dr. Siemers is a current member of the New York Academy of Sciences Alzheimer’s Disease Leadership Counsel. He participated as a member of the NIA working group that proposed criteria for preclinical Alzheimer’s disease in 2011. He is a past member of the Board of Directors of the American Society of Experimental Neurotherapeutics.